Emilie Lasson

Rab Diagnostics specializes in biomarker development for oncology-focused Antibody-Drug Conjugates (ADCs). Through our proprietary RabCANCER platform and deep expertise in intracellular drug trafficking, we provide high-quality, mechanism-driven insights to accelerate drug development and enable precision medicine. We bridge the gap between preclinical discoveries and clinical implementation by developing robust research tools and diagnostic kits, translating insights into clinical solutions. Based on world class science at Oslo University Hospital and headquartered in Oslo, Norway, collaborative partnerships and scientific rigor are in our DNA. We support biopharmaceutical companies in delivering precise, effective cancer therapies to patients worldwide.

Labrida is developing and marketing a chitosan (biomarine) based medical device, for professional cleaning of dental implants and teeth. Labrida BioClean® is a CE-marked, patented chitosan brush used by clinicians and dental professionals for maintenance of dental implants and/or teeth. Labrida BioClean® is sold to dental clinics in several markets in Europe. Through a milestone distribution agreement and partnership with Straumann (www.straumann.com), Labrida expects to face substantial growth in distribution and sales of Labrida BioClean® going forward. Labrida is a privately held company with 39 shareholders and holds its headquarter in Oslo, Norway. Labrida AS is ISO 13485:2016 certified.

We develop blood-based biomarkers for the early detection of neurodegenerative diseases. Our first product detects Alzheimer's disease before clinical symptoms appear.

The Centre for Digital Life Norway transforms Norwegian biotechnology research and education to increase innovation and value creation for society. The centre has research projects all over the country. Transdisciplinary collaboration is our trademark.

Rab Diagnostics specializes in biomarker development for oncology-focused Antibody-Drug Conjugates (ADCs). Through our proprietary RabCANCER platform and deep expertise in intracellular drug trafficking, we provide high-quality, mechanism-driven insights to accelerate drug development and enable precision medicine. We bridge the gap between preclinical discoveries and clinical implementation by developing robust research tools and diagnostic kits, translating insights into clinical solutions. Based on world class science at Oslo University Hospital and headquartered in Oslo, Norway, collaborative partnerships and scientific rigor are in our DNA. We support biopharmaceutical companies in delivering precise, effective cancer therapies to patients worldwide.

Labrida is developing and marketing a chitosan (biomarine) based medical device, for professional cleaning of dental implants and teeth. Labrida BioClean® is a CE-marked, patented chitosan brush used by clinicians and dental professionals for maintenance of dental implants and/or teeth. Labrida BioClean® is sold to dental clinics in several markets in Europe. Through a milestone distribution agreement and partnership with Straumann (www.straumann.com), Labrida expects to face substantial growth in distribution and sales of Labrida BioClean® going forward. Labrida is a privately held company with 39 shareholders and holds its headquarter in Oslo, Norway. Labrida AS is ISO 13485:2016 certified.

We develop blood-based biomarkers for the early detection of neurodegenerative diseases. Our first product detects Alzheimer's disease before clinical symptoms appear.

The Centre for Digital Life Norway transforms Norwegian biotechnology research and education to increase innovation and value creation for society. The centre has research projects all over the country. Transdisciplinary collaboration is our trademark.